It is possible, and the precedence is set in aGvHD already. Ruxolitinib (you know, the drug that Mesoblast refuses to dare compete with via a randomised, controlled trial) achieved such a feat in 2019. And their trial only enrolled 49 patients!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.005(3.13%) |
Mkt cap ! $36.15M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $29.44K | 183.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 141461 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 8655 | 3 |
View Market Depth
| Last trade - 11.08am 25/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |